Sandoz Aktie 124359842 / CH1243598427
Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
28.08.2025 07:00:14
|
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options
Sandoz Group AG
/ Key word(s): Product Launch
Media Release
Basel, August 28, 2025 – Sandoz (SIX: SDZ/OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today announced the launch of generic rivaroxaban in Germany, in new generic strengths of 10 mg, 15 mg and 20 mg. Rivaroxaban - 1 A Pharma®offers patients in Germany a high-quality, affordable alternative to reference product Xarelto®*, with a list price advantage across all three strengths.
Following successful litigation in Germany, where Sandoz was the first company to challenge the relevant dosage patent3, this launch marks a significant step in expanding access to high-quality, affordable anticoagulant therapies. Sandoz aims to introduce rivaroxaban in additional markets, supporting its Purpose of pioneering access for patients.
Thomas Weigold, Country President Germany, said: “After a 16-month delay, we can finally offer patients access to rivaroxaban in additional strengths. We are very pleased that we have successfully challenged the patent, because every day lost cost patients and the healthcare system in Germany unnecessary money.”
Rivaroxaban - 1 A Pharma® in the 2.5 mg strength was launched in Germany in April 2024, when the main patent expired. Since then, Bayer had been able to continue selling rivaroxaban in the higher and more popular strengths of 10 mg, 15 mg and 20 mg at monopoly prices, protected by preliminary injunctions based on the dosage patent, which was revoked on July 29, 2025.
The launch of these additional strengths marks a major milestone for Sandoz in Germany, where the company now offers the most comprehensive range of rivaroxaban film-coated tablets on the statutory health insurance market1. With this launch, Sandoz joins all open-house discount agreements for rivaroxaban in Germany, further supporting affordability and access for patients and payers.5
Rivaroxaban - 1 A Pharma® is an antithrombotic agent4. It is used in adults for stroke prevention in non-valvular atrial fibrillation (15 mg and 20 mg strengths), treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrence. The 10 mg strength is also indicated for prevention of venous thromboembolism in adults after elective hip or knee replacement surgery. In children and adolescents, the 15 mg and 20 mg strengths are used to treat venous thromboembolism and prevent its recurrence.4
* Xarelto® is a registered trademark of Bayer Intellectual Property GmbH.
DISCLAIMER This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.
REFERENCES 1 Most comprehensive range of rivaroxaban film-coated tablets on the German statutory health insurance market: Lauer Taxe, as of August 15, 2025, rivaroxaban film-coated tablets from 1 A Pharma and competitors, excluding hospital and sample packs
ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.
CONTACTS
End of Media Release |
Language: | English |
Company: | Sandoz Group AG |
Centralbahnstrasse 4 | |
4051 Basel | |
Switzerland | |
Internet: | www.sandoz.com |
ISIN: | CH1243598427 |
Valor: | 124359842 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2189424 |
End of News | EQS News Service |
|
2189424 28.08.2025 CET/CEST
Nachrichten zu Sandoz
29.09.25 |
Handel in Zürich: SLI zum Handelsende in der Gewinnzone (finanzen.ch) | |
29.09.25 |
Freundlicher Handel: SLI steigt zum Start des Montagshandels (finanzen.ch) | |
26.09.25 |
Handel in Zürich: SLI liegt nachmittags im Plus (finanzen.ch) | |
26.09.25 |
Handel in Zürich: SLI liegt im Plus (finanzen.ch) | |
25.09.25 |
Sandoz-Aktie unter Druck: Neues Eisenpräparat nun in den USA erhältlich (AWP) | |
23.09.25 |
SLI-Handel aktuell: SLI zeigt sich schlussendlich leichter (finanzen.ch) | |
23.09.25 |
Zurückhaltung in Zürich: SLI sackt am Dienstagmittag ab (finanzen.ch) | |
22.09.25 |
Zurückhaltung in Zürich: SLI präsentiert sich am Montagnachmittag schwächer (finanzen.ch) |
Analysen zu Sandoz
05.10.23 | Sandoz Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
05.10.23 | Sandoz Overweight | Morgan Stanley | |
05.10.23 | Sandoz Overweight | JP Morgan Chase & Co. |
Let’s talk about Börsenjahr 2025 | Börsentag Zürich 2025
Ein besonderes Highlight des Börsentag Zürich 2025 war die grosse Diskussionsrunde mit:
👉 Thomas B. Kovacs (Sparkojote)
👉 Robert Halver (Baader Bank)
👉 Tim Schäfer (Finanzblogger, New York)
👉 Lars Erichsen (Börsencoach & YouTuber)
👉 David Kunz (COO, BX Swiss)
Gemeinsam analysieren sie die Entwicklungen an den Finanzmärkten 2025, teilen Einschätzungen zu aktuellen Trends und geben spannende Einblicke für Anleger.
📌 Themen im Fokus:
🔹Welche Krisen & geopolitischen Risiken beschäftigen die Märkte wirklich?
🔹Wie wirken sich Zölle speziell auf die Schweiz und ihre Exportwirtschaft aus?
🔹Zinspolitik: Unterschiede zwischen USA, Europa und Schweiz.
🔹Aktien vs. Immobilien: Welche Assetklasse lohnt sich 2025 mehr?
🔹Künstliche Intelligenz – Hype oder langfristiger Wachstumstreiber?
🔹Gold vs. Bitcoin: Welches Asset ist der bessere Schutz im Depot?
🔹Inflation, Liquidität und Notenbanken: Warum Sachwerte profitieren.
🔹Blick in die Glaskugel: Wo stehen Aktien & Krypto Ende 2025?
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
US-Börsen schliessen mit Gewinnen -- SMI geht freundlich aus dem Handel -- DAX letztlich kaum verändert -- Asiens Börsen schliessen mehrheitlich festerZum Start in die neue Woche verbuchte der heimische Markt klare Aufschläge, wohingegen sich der deutsche Leitindex kaum bewegte. An den US-Börsen ging es leicht aufwärts. An den Märkten in Fernost ging es unterdessen überwiegend nach oben.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |